初次治疗后复发性喉癌的经口激光显微手术：一项系统评价和荟萃分析。

Transoral laser microsurgery for recurrent laryngeal carcinoma after primary treatment: A systematic review and meta-analysis.

作者信息

Zhong Anqiao, Xu Xiaohong, Fan Hongxia, Wang Lei, Niu Yikai

机构信息

Department of Respiratory Medicine, Yidu Central Hospital, Qingzhou, 262500, Shandong Province, China.

出版信息

J Cancer Res Ther. 2015 Oct;11 Suppl 2:C173-8. doi: 10.4103/0973-1482.168180.

DOI:10.4103/0973-1482.168180

PMID:26506871

Abstract

PURPOSE

To evaluate the efficacy and oncologic outcomes of transoral laser microsurgery (TLM) for recurrent laryngeal carcinoma after previous treatment.

MATERIALS AND METHODS

A systematic search in PubMed was performed using mesh word for "laryngeal cancer," crossed with "recurrent," and "TLM." The primary endpoints, including overall survival (OS) rate, local control rate, and disease-specific survival (DSS) were summarized using RevMan software. Adverse events and complications were recorded if reported.

RESULTS

The pooled odds ratios (ORs) for main outcomes, including local control, 5-year OS, and DSS were 3.08 (95% confidential indexed [95% CI], 1.88-5.05), 2.29 (95% CI, 1.42-3.67), and 5.05 (95% CI, 2.75-9.27), respectively. The pooled OR for functional outcome, larynx preservation, was 3.82 (95% CI, 2.46-5.94), whereas the pooled risk difference of local recurrence was 45% (95% CI, 26-64%).

CONCLUSIONS

It seems that TLM is an effective option for recurrent laryngeal cancer with regard to the high incidence of OS, local control, and especially organ preservation. However, more prospective studies are needed to confirm its efficiency.

摘要

目的

评估经口激光显微手术（TLM）治疗既往治疗后复发性喉癌的疗效及肿瘤学结局。

材料与方法

在PubMed中进行系统检索，使用主题词“喉癌”与“复发”以及“TLM”交叉检索。使用RevMan软件总结主要终点，包括总生存率（OS）、局部控制率和疾病特异性生存率（DSS）。若有报告，则记录不良事件和并发症。

结果

主要结局的合并比值比（OR），包括局部控制、5年OS和DSS分别为3.08（95%可信区间[95%CI]，1.88 - 5.05）、2.29（95%CI，1.42 - 3.67）和5.05（95%CI，2.75 - 9.27）。功能结局（喉保留）的合并OR为3.82（95%CI，2.46 - 5.94），而局部复发的合并风险差异为45%（95%CI，26 - 64%）。